News and Press Releases
Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
19 March 2026 -- New York, US and Sydney, Australia -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. today announced its...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2026
MAPS Sends Expert Delegation to United Nations Commission on Narcotic Drugs
MAPS delegation includes senior researchers, policy experts, and Veterans from the US, Europe, Australia, and the Middle East The CND is a central drug policy-making body in the UN, playing...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026
3141 Stevens Creek Blvd #40563, San Jose, CA 95117
Tilray Medical Launches Tilray Craft: Introducing High THC, High Terpene Genetics to the German Medical Cannabis Market
11 March 2025 -- Neumünster, Germany -- Tilray Medical, a division of Tilray Brands, Inc and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare...
Category: Other, Pharmaceutical
Posted: March 11, 2025
Cymphony is urgently advocating for improved communication to meet the rapidly growing demand from Gen Z and Millennial patients
Now more than ever, patients are seeking timely and efficient ways to communicate with their healthcare providers 20 January 2025 -- Crewe, UK -- Given the recent uptick in private...
Category: Logistics, Other, Pharmaceutical
Posted: January 20, 2025
TekniPlex Healthcare Becomes First to Introduce Medical-grade, ISCC PLUS-certified Bio-based PVC Compounds Equivalent to Conventional PVC
Company’s bio-based compounds are a drop-in replacement for a variety of injection molded or extruded medical-grade PVC compounds utilized in tubing, films, components and other applications. 3 October 2024 –Wayne,...
Category: BioManufacturing, Manufacturing and Packing
Posted: October 16, 2024
Industrielaan 37 B-9320 Erembodegem Belgium Tel: +32 (0)53 650711 VAT 0425.537.515
atai Life Sciences Announces Update on Beckley Psytech’s phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from phase 1 and First Patients Dosed in phase 2a
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable and shorter treatment paradigm of approximately two hours The...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 21, 2024
Numinus Wellness Announces Strategic Acquisition of MedBright AI
Plans name change to "Numinus Intelligence" leveraging its current revenue-generating operations to AI-enable mental health clinics across the US The strategic combination merges MedBright's AI-enabled clinical solution capabilities with Numinus'...
Category: Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024
Lyphe and Gro-Vida Announce Partnership to Enhance Medical Cannabis Access
13 June 2024 -- London, UK -- Lyphe Clinic is thrilled to announce its partnership with Gro-Vida, a licensed medical cannabis cultivar. Lyphe Clinic is a leading medical cannabis clinic based...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 13, 2024
First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
